For the treatment of Sepsis, MediSieve plans to use a combination of different magnetic particles to target both the pathogens that are the root cause of the disease and the cytokines that drive the immune response.

Sepsis is caused by pathogens from an infection which circulate in a patient’s bloodstream. These can elicit a dysregulated immune response that can escalate to multiple organ failure and death. The challenge in Sepsis is that both the pathogens (typically bacteria) and the body’s own response contribute to the disease. The destruction of bacteria by the immune system or antibiotics creates large quantities of endotoxins, which aggravate the immune response and can escalate Sepsis even while treatment is being given.

Broad risk groups

Newborns & Pregnant Women

Inpatients

Significant worldwide burden

30m infected annually
6m deaths

High morbidity and mortality

Mortality rate 30%

Multiple organ failure

Long patient care

Negative trend

Costly treatment

Antibiotic resistance

The combination of functionalised MBs and MediSieve’s extracorporeal filter can reverse the initial impact of Sepsis – removing bacteria, endotoxins and the byproducts of the dysregulated immune response. Removing these causative agents from the bloodstream offers the potential of a novel treatment that can rapidly target both the pathogens and the dysregulated immune response to improve the treatment of Sepsis.

Latest News

MediSieve Receives Approval for First-in-Man Clinical Investigation

MediSieve Receives Approval for First-in-Man Clinical Investigation
May 24, 2022

Radboud University Medical Center will perform the first trial of the Novel Magnetic Haemoflitration System.
MediSieve Receives Industry Recognition

MediSieve Receives Industry Recognition
April 02, 2022

MediSieve, a biotech company that has developed an innovative blood filtration device, receives recognition and approval from the industry.